Early research shows potential CLL drug with peculiar properties

Preclinical research out of the University of Ireland, Galway, hints at a molecule with the potential to do incredible things for people diagnosed with chronic lymphocytic leukemia (CLL).

Researchers discovered that the molecule, known as PHA-767491 has some peculiar qualities when it meets up with circulating leukemia cells, qualities that other treatments in many cases have lacked, for one reason or another, such as:

-- Not only does it kill basic leukemic cells, it also appears to kill leukemic cells that have features often associated with chemotherapy resistance-- a potentially major step forward;
-- It also can target leukemic cells that are undergoing cell division within the lymph nodes, cells that typically are beyond the reach of current treatment modalities and often wind up serving as hiding reservoirs for progressively treatment-resistant cells.

Researchers were sufficiently convinced of the molecule's efficacy that they applied for and were granted a Phase I clinical trial of the molecule's parent compound at the HRB Clinical Research Facility at NUI Galway.

The reader should keep in mind that many different molecules prove effective at killing cancer cells in the lab and in animal studies but very few reach actual human trials.

Source: Medical News Today
Check out: The HRB Clinical Research Facility at NUI Galway

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap